Professional Documents
Culture Documents
Interview
Interview
Biozeen has a foot print in 11 countries. Major markets fall in the Far East, Oceania,
Africa and Latin America, global business accounted for 80 per cent of Biozeen’s
business with 20 per cent from the domestic market.
Aim is to make the company manufacture vaccine which is affordable and easily
available to the public.
Reduced costs will increase production, and increase availability of vaccines for the
global population.
Currently, one in every three vaccines in the world is made using BiOZEEN’s
technology – which has reduced costs by 15% to 30%.
The laws of each country contribute majorly in this question. Regulations and tax
directly affect prices.
6) Do government policies in various countries affect your business? and in what way?
In the global front, there is a huge market potential for US exports as of now.
However, barriers are there like price controls of medicines and few other non-
tariff barriers.
There are lot of government regulatory bodies, which we need to comply with.
You can check website for more details. (Department of Scientific and
Industrial Research, ISO 9001:2015, American Society of Mechanical
Engineers)
However, we believe in India’s growth story. Pharmaceutical companies are
expected to outperform in the coming years, improving our business in India.
7) Are there any intellectual property protection available for biopharma medical equipment
manufactures in India?
I think there are intellectual property protection for few of our equipment. If a
company thinks they need IP protection, then they can file one.
Credits: